ANIK
Anika Therapeutics, Inc. NASDAQ Listed May 3, 1993$15.13
After hrs
$14.77
+0.00%
Mkt Cap $201.3M
52w Low $7.87
86.7% of range
52w High $16.24
50d MA $14.55
200d MA $10.76
P/E (TTM)
-19.5x
EV/EBITDA
-57.0x
P/B
1.5x
Debt/Equity
0.2x
ROE
-7.6%
P/FCF
31.6x
RSI (14)
—
ATR (14)
—
Beta
0.28
50d MA
$14.55
200d MA
$10.76
Avg Volume
144.0K
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
32 Wiggins Avenue · Bedford, MA 01730 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | TNS | -0.07 | 0.27 | +485.7% | 12.39 | +2.4% | +0.5% | +19.9% | +17.4% | +20.7% | +22.0% | — |
| Feb 26, 2026 | TNS | -0.12 | 0.31 | +348.0% | 12.79 | -0.9% | +12.3% | +12.0% | +12.6% | +12.3% | +11.4% | — |
| Nov 5, 2025 | TNS | 0.02 | 0.04 | +100.0% | 9.85 | +0.2% | -1.0% | +0.0% | +2.2% | +2.8% | +2.5% | — |
| Jul 30, 2025 | TNS | -0.13 | -0.13 | +0.0% | 8.10 | +0.0% | +2.0% | +6.7% | +8.3% | +3.1% | +1.9% | — |
| May 9, 2025 | TNS | 0.09 | -0.06 | -166.7% | 11.64 | +5.0% | +1.8% | +6.6% | -2.7% | +5.2% | +4.7% | — |
| Mar 12, 2025 | TNS | -0.01 | -0.03 | -200.0% | 17.11 | -4.1% | -11.1% | -7.0% | -5.8% | -7.3% | -6.8% | — |
| Oct 31, 2024 | TNS | 0.30 | -0.25 | -183.3% | 17.11 | +0.4% | -3.4% | -0.2% | -4.7% | +0.9% | +0.7% | — |
| Aug 8, 2024 | TNS | 0.23 | 0.17 | -26.1% | 25.68 | -1.9% | +0.0% | -2.4% | -2.6% | -1.5% | -0.5% | — |
| May 8, 2024 | TNS | -0.19 | -0.31 | -63.2% | 28.47 | -5.5% | -11.3% | -10.0% | -10.2% | -10.1% | -8.4% | — |
| Mar 13, 2024 | TNS | -0.26 | -4.30 | -1553.8% | 25.40 | -6.0% | -3.4% | +0.2% | -0.5% | -0.1% | +0.7% | — |
| Nov 2, 2023 | TNS | -0.33 | -0.45 | -36.4% | 18.99 | +27.5% | +11.2% | +11.6% | +10.5% | +9.2% | +7.4% | — |
| Aug 8, 2023 | TNS | -0.34 | -0.19 | +44.1% | 21.05 | +1.4% | -4.9% | -11.8% | -12.7% | -8.7% | -12.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 27 | Barrington Research | Maintains | Outperform → Outperform | — | $12.79 | $12.67 | -0.9% | +12.3% | +12.0% | +12.6% | +12.3% | +11.4% |
| Jan 9 | Barrington Research | Maintains | Outperform → Outperform | — | $9.55 | $9.58 | +0.3% | -0.3% | -1.5% | +0.0% | -0.1% | -0.2% |
| Nov 6 | Barrington Research | Maintains | Outperform → Outperform | — | $9.85 | $9.87 | +0.2% | -1.0% | +0.0% | +2.2% | +2.8% | +2.5% |
| Sep 23 | Barrington Research | Maintains | Outperform → Outperform | — | $9.34 | $9.34 | +0.0% | -2.4% | -2.9% | -3.6% | -3.4% | -2.1% |
| Jul 31 | Barrington Research | Maintains | Outperform → Outperform | — | $8.10 | $8.10 | +0.0% | +2.0% | +6.7% | +8.3% | +3.1% | +1.9% |
| May 12 | Barrington Research | Maintains | Outperform → Outperform | — | $11.64 | $12.22 | +5.0% | +1.8% | +6.6% | -2.7% | +5.2% | +4.7% |
| Mar 13 | Barrington Research | Maintains | Outperform → Outperform | — | $17.11 | $16.41 | -4.1% | -11.1% | -7.0% | -5.8% | -7.3% | -6.8% |
| Nov 1 | Barrington Research | Maintains | Outperform → Outperform | — | $17.11 | $17.18 | +0.4% | -3.4% | -0.2% | -4.7% | +0.9% | +0.7% |
| Oct 22 | Barrington Research | Maintains | Outperform → Outperform | — | $24.44 | $24.48 | +0.2% | +1.1% | +0.4% | +0.3% | -0.5% | +0.9% |
| Aug 9 | Barrington Research | Maintains | Outperform → Outperform | — | $25.68 | $25.19 | -1.9% | +0.0% | -2.4% | -2.6% | -1.5% | -0.5% |
| May 29 | Stephens & Co. | Maintains | Equal Weight → Equal Weight | — | $24.76 | $24.96 | +0.8% | +3.6% | +3.8% | +3.6% | +7.8% | +6.6% |
| May 9 | Barrington Research | Maintains | Outperform → Outperform | — | $28.47 | $26.91 | -5.5% | -11.3% | -10.0% | -10.2% | -10.1% | -8.4% |
| Mar 14 | Barrington Research | Maintains | Outperform → Outperform | — | $25.40 | $23.87 | -6.0% | -3.4% | +0.2% | -0.5% | -0.1% | +0.7% |
| Mar 14 | Stephens & Co. | Maintains | Equal Weight → Equal Weight | — | $25.40 | $23.87 | -6.0% | -3.4% | +0.2% | -0.5% | -0.1% | +0.7% |
| Jan 3 | Barrington Research | Maintains | Outperform → Outperform | — | $22.66 | $22.59 | -0.3% | -0.1% | -2.0% | -2.6% | -0.2% | -0.9% |
| Nov 3 | Barrington Research | Maintains | Outperform → Outperform | — | $18.99 | $24.21 | +27.5% | +11.2% | +11.6% | +10.5% | +9.2% | +7.4% |
| Aug 14 | Barrington Research | Upgrade | Market Perform → Outperform | — | $18.38 | $19.40 | +5.5% | +4.5% | +0.7% | +0.7% | +0.5% | +2.3% |
| Aug 10 | Stephens & Co. | Maintains | Equal Weight → Equal Weight | — | $20.01 | $20.00 | -0.1% | -7.2% | -8.1% | -4.0% | -7.5% | -7.5% |
| May 31 | Stephens & Co. | Maintains | Equal Weight → Equal Weight | — | $27.06 | $26.97 | -0.3% | +0.1% | -1.3% | +0.8% | -1.2% | -0.4% |
| Mar 7 | Barrington Research | Downgrade | Outperform → Market Perform | — | $28.87 | $27.63 | -4.3% | -10.3% | -6.0% | -6.8% | -9.6% | -9.8% |
| Nov 9 | Barrington Research | Upgrade | Market Perform → Outperform | — | $27.37 | $28.21 | +3.1% | +8.1% | +16.6% | +13.5% | +12.6% | +14.2% |
| Mar 9 | Stephens & Co. | Downgrade | Overweight → Equal Weight | — | $30.60 | $28.75 | -6.0% | -14.3% | -19.3% | -16.4% | -16.8% | -17.1% |
| Dec 16 | Barrington Research | Upgrade | Market Perform → Outperform | — | $39.27 | $41.39 | +5.4% | +4.3% | +7.1% | +14.1% | +9.0% | +12.4% |
| Jan 21 | Sidoti & Co. | Upgrade | Neutral → Buy | — | $45.43 | $46.60 | +2.6% | +1.0% | +0.6% | +1.2% | -3.4% | -2.1% |
| Sep 23 | First Analysis | Downgrade | Strong Buy → Outperform | — | $53.12 | $51.86 | -2.4% | -0.4% | -0.7% | -0.0% | +0.6% | +1.5% |
| Feb 22 | Sidoti & Co. | Downgrade | Buy → Neutral | — | $40.49 | $37.27 | -8.0% | -16.2% | -17.6% | -19.7% | -18.0% | -19.4% |
| Jul 27 | Barrington Research | Upgrade | Market Perform → Outperform | — | $40.68 | $42.45 | +4.4% | -1.5% | -3.1% | -1.6% | -0.4% | -0.3% |
| Jun 20 | First Analysis | Downgrade | Overweight → Equal Weight | — | $46.12 | $33.32 | -27.8% | -37.6% | -35.5% | -32.8% | -33.5% | -31.8% |
| May 4 | Barrington Research | Upgrade | Market Perform → Outperform | — | $34.80 | $36.14 | +3.9% | +8.8% | +9.3% | +5.6% | +5.2% | +6.3% |
| Feb 23 | Barrington Research | Downgrade | Outperform → Market Perform | — | $57.71 | $49.02 | -15.1% | -10.4% | -7.6% | -6.0% | -9.8% | -10.7% |
| Jan 24 | First Analysis | Upgrade | Equal Weight → Overweight | — | $59.38 | $60.00 | +1.0% | +3.5% | +5.1% | +14.1% | +15.2% | +14.9% |
| Apr 27 | Northland Capital Markets | Downgrade | Outperform → Market Perform | — | $46.71 | $45.91 | -1.7% | -4.4% | +0.5% | -2.2% | -2.4% | -4.3% |
| Apr 27 | Northland Securities | Downgrade | Outperform → Market Perform | — | $46.71 | $45.91 | -1.7% | -4.4% | +0.5% | -2.2% | -2.4% | -4.3% |
| Feb 26 | Northland Securities | Maintains | Outperform → Outperform | — | $43.37 | $43.47 | +0.2% | +7.0% | +4.1% | +3.7% | +3.3% | +4.9% |
| Feb 26 | Northland Capital Markets | Maintains | Outperform → Outperform | — | $43.37 | $43.47 | +0.2% | +7.0% | +4.1% | +3.7% | +3.3% | +4.9% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 1, 2026 | HENNEMAN JOHN B III | — | Buy | 5,000 | $14.66 | $73K | 54,871 | +2.75% | — |
| Apr 30, 2026 | Griffin Stephen D. | President and CEO | Buy | 12,200 | $12.29 | $150K | 36,163 | +19.28% | +21.61% |
Data updated apr 24, 2026 6:10pm
· Source: massive.com